Multidisciplinary problems of rheumatology and pulmonology
- Authors: Ananyeva LP1
-
Affiliations:
- ФГБНУ «НИИ ревматологии им. В.А. Насоновой»
- Issue: Vol 89, No 5 (2017)
- Pages: 4-9
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32156
- DOI: https://doi.org/10.17116/terarkh20178954-9
- ID: 32156
Cite item
Full Text
Abstract
Damage to the respiratory system worsens prognosis and increases mortality in all systemic immunoinflammatory rheumatic diseases (SIRDs). Leading pulmonary manifestations in each disease are different, so the typical picture of each nosological entity is very peculiar. In all SIRDs, the disease starts with lung involvement in 10—20% of cases, preceding the expanded clinical presentation of a systemic disease. At a certain stage, lung damage may be the only manifestation of the disease or predominate in its clinical picture, determining the severity of a condition. Among the patients referred to consultation with a pulmonologist for interstitial lung disease, about 15% have manifestations of SIRDs that is confirmed by a special survey. The paper discusses the diagnostic features of SIRDs with lung involvement, as well as indications for consultation with a rheumatologist. The key clinical symptoms indicating a possible rheumatic disease in patients with lung involvement are considered. Evidence for the main circulating autoantibodies identifiable in high titers in patients with SIRDs in a serological test is given and its positivity is interpreted. The issues associated with the term «undifferentiated connective tissue diseases-associated interstitial lung disease» are discussed; the expediency of using the term «interstitial pneumonia with autoimmune signs (AIS)» is emphasized. The clinical characteristics of and classification criteria for AIS are presented. The prognosis and outcomes of interstitial pneumonias of varying etiologies, as well as the importance of the multidisciplinary approach to managing patients with SIRDs and lung involvement, which improves the quality of diagnosis, adequacy of treatment, and quality of life, are dealt with.
Full Text
##article.viewOnOriginalSite##References
- Wells AU, Denton CP. Interstitial lung disease in connective tissue disease — mechanisms and management. Nat Rev Rheumatol. 2014;10(12):728-739. doi: 10.1038/nrrheum.2014.149
- Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380:689-698. doi: 10.1016/S0140-6736(12)61079-4
- Mittoo S, Gelber AC, Christopher-Stine L, Horton MR, Lechtzin N, Danoff SK. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med. 2009;103:1152-1158. doi: 10.1016/j.rmed.2009.02.009
- Castellino F, Goldberg H, Dellaripa PF. The impact of rheumatologic evaluation in the management of patients with interstitial lung disease. Rheumatology. 2010;50:483-493. doi: 10.1093/rheumatology/keq233
- Генно-инженерные биологические препараты в лечении ревматоидного артрита. Под ред. академика РАМН Е.Л. Насонова. М.: ИМА-ПРЕСС; 2013:123-138.
- Клинические рекомендации. Ревматология. 2-е издание, исправленное и дополненное. Под ред. акад. РАМН Е.Л. Насонова. М.: ГЭОТАР-Медиа; 2010.
- Raghu G, Rochwerg B, Zhang Y, Garcia C.A. C, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL. An Official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3-19. doi: 10.1164/rccm.201506-1063st
- Corte TJ, Copley SJ, Desai SR, Zappala CJ, Hansell DM, Nicholson AG, Colby TV, Renzoni E, Maher TM, Wells AU. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J. 2012;39:661-668. doi: 10.1183/09031936.00174910
- Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: A review. Respirology. 2015;21:245-258. doi: 10.1111/resp.12588
- Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease BMJ. 2016;352:h6819. doi: 10.1136/bmj.h6819
- Kinder BW, Shariat C., Collard HR, Koth LL, Wolters PJ, Golden JA, Panos RJ, King TE. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Lung. 2010;188(2):143-149. doi: 10.1007/s00408-009-9226-7
- Fischer AA, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Strek ME, Golden JA. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46:976-987. doi: 10.1183/13993003.00150-2015
- Ferri C, Manfredi A, Sebastiani M, Colaci M, Giuggioli D, Vacchi C, Della Casa G, Cerri S, Torricelli P, Luppi F. Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature. Autoimmun Rev. 2016;15(1):61-70. doi: 10.1016/j.autrev.2015.09.003
- Oldham JM, Adegunsoye A, Valenzi E, Lee C, Witt L, Chen L, Husain AN, Montner S, Chung JH, Cottin V, Fischer A, Noth I, Vij R, Strek ME. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J. 2016;47(6):1767-1775. doi: 10.1183/13993003.01565-201
- Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011;140(5):1292-1299. doi: 10.1378/chest.10-2662
- Assayag D, Kim EJ, Elicker BM, Jones KD, King TE, Koth LL, Shum AK, Wolters PJ, Collard HR, Lee JS. Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria. Respir Med. 2015;109(10):1326-1331. doi: 10.1016/j.rmed.2015.08.010